patent.fyi
Applications  /  US 2026/0355310
United States Patent Application Publication

US 2026/0355310 A1

Published
Nov 12, 2026
Filed
Oct 27, 2023
Earliest date on the face
Oct 28, 2022
Classification
A61K 39/3955
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Proximal tubular transport inhibition

What ifWhat if an oral sodium–glucose cotransporter 2 inhibitor supplied the kidney hemodynamic effect?
Claim language“an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof”

The inhibitor reduces sodium and glucose reabsorption in the proximal tubule and increases sodium chloride delivery to the macula densa. Tubuloglomerular feedback lowers intraglomerular pressure and reduces protein filtration.

1.1Angiotensin converting enzyme inhibition

What ifWhat if an oral angiotensin converting enzyme inhibitor supplied the antiproteinuric effect?
Claim language“an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof”

Enzyme inhibition reduces angiotensin II formation and lowers efferent arteriolar resistance. The resulting decrease in glomerular capillary pressure reduces urinary protein loss.

1.1Soluble receptor fusion protein

What ifWhat if a soluble receptor fusion protein captured circulating APRIL?
Claim language“APRIL binding antibody or an antigen-binding fragment thereof”

The fusion protein contains the extracellular ligand-binding domain of a B-cell receptor for APRIL and BAFF joined to an immunoglobulin constant region. The receptor domain sequesters both soluble ligands and reduces their availability to cell-surface receptors.

1.1Ileal glucocorticoid delivery

What ifWhat if a delayed-release oral glucocorticoid reduced the mucosal immune activity that contributes to pathogenic IgA production?
Claim language“APRIL binding antibody or an antigen-binding fragment thereof”

Coated particles release a glucocorticoid in the distal ileum near gut-associated lymphoid tissue. The drug activates intracellular glucocorticoid receptors and suppresses local immune activity associated with production of galactose-deficient IgA1.

1.1Angiotensin receptor blockade

What ifWhat if a selective angiotensin II type 1 receptor blocker reduced glomerular pressure?
Claim language“an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof”

An oral small molecule blocks angiotensin II signaling at the type 1 receptor. Reduced efferent arteriolar tone lowers glomerular capillary pressure and decreases proteinuria.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Combination testing in a perfused glomerulus model

A research platform couples a human B-cell culture chamber to a perfused glomerular barrier formed by endothelial cells and podocytes. The APRIL-binding antibody enters the B-cell chamber, and the endothelin receptor antagonist enters the vascular channel of the glomerular module. Conditioned medium from the B-cell chamber feeds the vascular channel through a mixing junction. The platform measures secreted IgA at the B-cell outlet and albumin passage across the glomerular barrier.

Component substitution

Soluble TACI fusion as the APRIL binder

A recombinant TACI–Fc fusion replaces the APRIL-binding antibody and pairs with the endothelin receptor antagonist. The fusion contains the extracellular ligand-binding domain of TACI joined to an immunoglobulin Fc domain that supports dimerization. The soluble fusion binds APRIL and BAFF, while the antagonist blocks endothelin receptor signaling.

Parameter or scale variation

Comparison of concurrent and staggered exposure

Two parallel groups of perfused renal co-cultures compare the timing of exposure to the antagonist and the antibody. The concurrent group receives both agents at hour 0, and the staggered group receives the antagonist at hour 0 and the antibody at hour 24. Antagonist and antibody exposure last 72 and 48 hours, respectively, in both groups. Samples collected at hours 0, 24, 48, and 72 track secreted IgA and albumin passage across the barrier.

Combination with existing systems

Combination tracking in a renal registry

A renal registry links antagonist dispensing records and antibody administration records to the same participant identifier. The registry imports urine protein and creatinine results, estimated glomerular filtration rate, and blood pressure with their observation dates. The interface plots these measurements against treatment start dates and documented interruptions.

Separate delivery through a home administration kit

A home administration kit combines a calendar blister pack for an oral antagonist with a prefilled autoinjector for a subcutaneous APRIL-binding antibody formulation. The blister pack marks each scheduled oral administration, and the autoinjector delivers a fixed volume through a shielded needle. The two containers retain separate labeling and storage instructions, and each agent follows its own administration schedule.

Automated or data-driven variant

Robotic screening of paired agent concentrations

A liquid-handling robot dispenses an endothelin receptor antagonist and an APRIL-binding antibody from separate stock plates into matched B-cell and glomerular cell assay plates. A plate map assigns each concentration pair to replicate wells and includes vehicle and single-agent controls. The robot transfers conditioned medium from the B-cell wells to the corresponding glomerular wells. Analysis software maps IgA and barrier permeability measurements back to the concentration pairs.

Specific version of a part

Selective endothelin receptor blockade

An oral small molecule preferentially blocks the endothelin type A receptor. The blockade reduces endothelin-1 signaling in vascular smooth muscle and limits endothelin-mediated vasoconstriction.

Dual receptor antagonist tablet

A single oral small molecule blocks both the endothelin type A receptor and the angiotensin II type 1 receptor. A separately administered APRIL-binding antibody binds soluble APRIL and reduces its availability for receptor signaling.

Subcutaneous APRIL neutralizing antibody

A sterile buffered solution delivers a full-length monoclonal immunoglobulin by subcutaneous injection. Its two antigen-binding sites bind soluble APRIL and reduce APRIL signaling through receptors on antibody-secreting cells.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2006/0009512 A1
Published
Jan 12, 2006
Filed
Oct 6, 2003
Class
A61K 31/405
Document BUS 8,173,593 B2
Published
May 8, 2012
Filed
Jul 19, 2006
Class
A61K 38/00
Claim 1
Document A
Document B
1.1administering to the subject an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and an APRIL binding antibody or an antigen-binding fragment thereof.
Therefore according to the present invention, there is provided a method of treating cancer, in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof in combination with an effective amount of a 5-HT1B/1D receptor agonist, or a pharmaceutically acceptable salt thereof.
A · US 2006/0009512 A1 · ¶ 77
A first aspect of the present invention is directed to a method for emergency contraception, comprising administering to a female in need thereof an effective amount of an endothelin receptor antagonist.
B · US 8,173,593 B2 · ¶ 11

An empty cell means only that no passage was reproduced there.

Statements in these documents
The present invention relates to the use of a 5-HT1B/1D receptor agonist, or a pharmaceutically acceptable salt thereof in the treatment or prevention of headache that results from administering an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof.
A · US 2006/0009512 A1 · ¶ 1
Recently, endothelin A receptor antagonists have been identified as potentially of value in the treatment of cancer (Cancer Research, 56, 663-668, Feb. 15th, 1996 and Nature Medicine, Volume 1, Number 9, Sep. 1999, 944-949).
A · US 2006/0009512 A1 · ¶ 6
The studies showed that two pharmaceutical compositions containing 0.75-0.75 mg of levonorgestrel used at 12 hours' interval within 72 hours after the unprotected coitus successfully inhibited the conceptions which otherwise might have occurred.
B · US 8,173,593 B2 · ¶ 8
The results of the studies showed that the prescription of the 12 hour interval between the two doses decreased the compliance.
B · US 8,173,593 B2 · ¶ 8
Cite aspatent.fyi, US 2026/0355310 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355310/, SHA-256 a8c27b6ea36a5fcf06b360853ae7ac12e0756827a5c47a0835b2646858598cfe
First published
Permanent addresshttps://patent.fyi/US20260355310/
Content fingerprint (SHA-256)a8c27b6ea36a5fcf06b360853ae7ac12e0756827a5c47a0835b2646858598cfe
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi